XOMA Corporation (XOMA)

[KeepOn]

XOMA $29.85 — bouncing from the Dec 11 RZLT drop ($25.39), filling the gap but $31 is key for trend confirmation. Don’t forget the preferreds (XOMAO/XOMAP) just paid $0.52+ per quarter (~8% yield), so income investors are covered. Common stock is showing life thanks to growing royalties from Vabysmo & Ojemda (~$38M) and new acquisitions like Mural Oncology & Turnstone, which add optionality while partners take the R&D risk. The Pomerantz probe is a caution flag, but long-term, XOMA is a portfolio play, not a single-trial biotech. Dip $28 = buy, stop $27, target $35–$36 if approvals & milestones hit. Patience still pays here. 🚀